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Sum m ary
An 18-year-old boy with X-linked chronic granulomatous disease (CGD) developed 
Aspergillus fumigatus pneumonia and multifocal osteomyelitis. Treatment with 
amphotericin B resulted in only moderate improvement of the lesions and was 
accompanied by considerable toxicity. In contrast, administration of the new triazole 
drug itraconazole led to complete disappearance of all signs of infection. We conclude 
that itraconazole may be a valuable new drug for treating invasive aspergillosis in 
patients with CGD, although the duration of treatment remains to be established.
Introduction
Chronic granulom atous disease (C G D ) is a rare disorder which usually 
becomes m anifest early in childhood and is characterised by recurren t 
infections . 1 T h e  m ost com m on causative agents are Staphylococcus aureus3 
Enterobacteriaceae and fungi. In  a review of 245  patients with C G D , the 
incidence of fungal infections was 20*5 % 3 m ost being caused by species of 
Aspergillus.2 Since m ortality  from  bacterial infections can be largely prevented 
by the prophylactic adm inistration of co-trimoxazole, Aspergillus infections 
now form  the m ost im portan t cause of death for patients with C G D .3 
A m photericin  B, a widely used antifungal drug for treating these infections, 
has several well-known side-effects, such as fever, chills^ nephrotoxicity, 
hypokalaemia, anaemia and throm bophlebitis.
Itraconazole is a new oral triazole antifungal drug that is effective against 
Aspergillus spp. in vitro , in experim ental animal models and in patien ts .4-6 T h e  
m ode of action of itraconazole, like that of the azoles, is inhibition of ergosterol 
synthesis in the fungal cell m em brane th rough binding to the cytochrome P- 
4 5 0 .7 In  this report we describe a patient with C G D  who developed invasive 
aspergillosis which persisted despite treatm ent with am photericin  B; the 
patient later responded favourably to itraconazole.
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Case report
An 18-year-old boy was referred to the Leiden U niversity  H ospital in April 
1 9 8 6 . In  1977  and 1978 , the patient was treated for pleural empyem a as well 
as subphrenic and liver abscesses caused by Staphylococcus aureus. A diagnosis 
of X -linked chronic granulom atous disease (C G D ) was made. T h is  was based 
on the defective killing of *S. aureus by the pa tien t’s granulocytes and deficient 
production  of hydrogen peroxide by these cells. Similar defects were 
dem onstrated in respect of his m other and his m aternal grandm other.
In  1979 , the patient was pu t on m aintenance therapy with co-trimoxazole 
w ithout fu rther bacterial infections. In  D ecem ber 1985 , he developed pain in 
the right shoulder and a non-productive cough. A chest X -ray  showed an 
infiltration in the right lower lobe. T h e  dose of co-trimoxazole was increased 
to four tablets daily. T h ree  m onths later the pa tien t’s condition deteriorated 
with fever, loss of weight, abdom inal pain and progressive coughing. T h ere  
was obvious extension of the pulm onary lesions in the right lower lobe. 
Aspergillus fumigatus was cultured  on several occasions from  puru len t 
discharge from  an old scar on the right chest wall. T h ere  were m ultiple bone 
lesions in the ribs as well as the left hum erus. A biopsy from  the left hum erus 
also yielded Aspergillus fumigatus.
T h e  patient was treated with am photericin  B intravenously (total cum ulative 
dose 20  m g/kg) and flucytosine (160  m g /k g  daily) for a period of 6 weeks. 
T rea tm en t with am photericin  B, which was complicated by recurren t chills, 
high fever and throm bophlebitis , resulted in only m oderate clinical im ­
provem ent. O n 30  April 1986 , the patient was transferred  to the U niversity  
H ospital of Leiden for fu rther treatm ent. Physical exam ination revealed a pale, 
ill, cachectic boy, tem perature 37-4 °C, body weight 48  kg. A part from  healed 
skin lesions on the right chest wall, the abdom inal wall and the right upper arm  
no abnormalities were found on clinical examination. T h e  E S R  was 75 m m /h , 
haem oglobin 7-8 g /d l,  leucocyte count 1 6 1  x i o 9/U serum  creatinine 
71 //mol/1 and serum  potassium  2*8 mmol/1. A chest X -ray  still showed 
extensive infiltration in the right lower lobe [Plate i(a)]. T rea tm en t with 
150 mg itraconazole twice daily was started. After a transfusion of 2 units of 
packed erythrocytes, the patient was discharged from  hospital. T h ree  weeks of 
treatm ent w ith itraconazole at hom e resulted in m arked clinical im provem ent. 
F our m onths after the start of treatm ent w ith itraconazole, all clinical signs of 
infection had disappeared and a chest X -ray  showed almost complete 
resolution of the infiltrate [Plate i(b)]. T h e  E S R  was 16 m m /h ,  haem oglobin 
12-3 g /d l,  leucocyte count 5-9 x i o 9/ l .  N o serious side-effects of itraconazole or 
abnormalities in laboratory tests were encountered. T h e  patient did, however, 
experience a short episode of m oderate loss of hair.
Plasma concentrations of itraconazole on the second day of treatm ent 
(determ ined by h igh-pressure liquid chrom atography) were 378  n g /m l before 
the dose, 442  n g /m l at 2 h, 665  n g /m l at 4  h, and 555  n g /1 at 6 h after the dose. 
A fter 3 weeks of treatm ent, the plasma concentration of itraconazole was 
1820  n g /m l 2 h  after a dose of 150 mg. T h e  patient has since been taking a 
m aintenance dose of itraconazole of 100 mg twice daily for 3 years w ithout any 
signs of recurrence of the fungal infection. In  this period, the bone lesions have 
completely resolved.
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Plate I .  Chest X-rays of a patient with CGD and aspergillosis at the start of treatment with
itraconazole (a) and 4 months later (b).
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D iscussion
Aspergillus infections in patients w ith C G D  are usually very difficult to trea t , 2 
probably because antifungal drugs are unable to cure the infection w ithout the 
contribu tion  of phagocytic cells. U n d er these circum stances, one would expect 
a fungicidal d rug  such as am photericin  B to be m ore effective than  a fungistatic 
drug  such as itraconazole. H ow ever, w hether a drug  is called fungistatic or 
fungicidal is based mainly on in-vitro  findings which do not necessarily reflect 
the efficacy of these drugs in v ivo .8 In  fact, contrary to the in-vitro  findings we 
have shown in an experim ental m odel of a dissem inated candidal infection that 
the triazoles, itraconazole and fluconazole, are as effective in norm al as in 
neutropenic  mice. A m photericin  B, however, is less active in neutropenic  mice 
than in norm al m ice .9
In  our patient, the infection did not respond well to a full course of 
am photericin  B whereas itraconazole was clearly effective. F o r patients with 
C G D , who often need trea tm en t for long periods, the oral adm inistra tion  of 
itraconazole is an obvious advantage of this d rug  over am photericin  B. As in 
healthy volunteers, the pharm acokinetic  findings on itraconazole in our 
patient were characterised by slow absorption  after oral adm inistra tion  of the 
drug  and a rise in plasm a concentrations after 3 weeks of treatm ent. T h e  
latter is probably  due to the large volum e of d is tribu tion  and the long half-life 
of the d ru g . 10 Because of this long half-life, a once-daily dose should be 
effective, although this has not been widely applied for serious infections so 
far. T h e  side effects of pro longed adm inistra tion  of itraconazole are usually 
m ild, consisting of nausea, dyspepsia and dizziness.' C om pared  with 
ketoconazole, itraconazole binds m uch  m ore selectively to the fungal 
cytochrom e P -4 5 0  than  to the hum an  cytochrom e P -4 5 0 .7 T h e re  is not, 
therefore, any interference w ith cholesterol synthesis so tha t endocrine side- 
effects, as seen in patients treated  w ith ketoconazole, are less likely. Loss of 
hair, as was seen in our patient, has been a ttr ibu ted  to itraconazole11 b u t can 
also arise during  recovery from  serious infections.
T h e  exact dura tion  of trea tm en t w ith itraconazole for patients w ith C G D  
and Aspergillus infections is difficult to establish because it rem ains uncertain  
w hether all the organism s have been elim inated from  the site of infection. 
Recurrences of Aspergillus infections after cessation of trea tm en t w ith 
am photericin  B, com m on in patients w ith C G D , are often very difficult to 
trea t .2 T herefo re , there  seems to be an im portan t role for itraconazole in the 
long-term  trea tm ent, and possibly prevention , o f Aspergillus infections in 
these patients.
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